Literature DB >> 10732293

An immunohistochemical study of the expression of bcl-2 and p53 oncoproteins in pancreatic intraepithelial neoplasia and pancreatic cancer.

R Tomaszewska1, D Karcz, J Stachura.   

Abstract

BACKGROUND: The bcl-2 and p53 gene deregulation is frequently involved in several types of malignancies. The purpose of this study was to evaluate the expression of bcl-2 and p53 genes in various types of pancreatic intraepithelial proliferation and in pancreatic cancer and to answer the question of whether they interact in the process of intraductal epithelial proliferation.
METHODS: Immunohistochemical staining for p53 and bcl-2 was performed on paraffin embedded sections from 56 patients operated on for pancreatic carcinoma, chronic pancreatitis, and other conditions.
RESULTS: Pancreatic cancer in 100% of cases showed p53 expression and in 27.7% bcl-2 expression. The p53 gene was expressed already in pancreatic intraductal neoplasia and its frequency was significantly rising with an increasing degree of hyperplasia. Normal epithelium of pancreatic ducts and ductules showed a high expression of bcl-2, which was decreasing in the process of intraductal proliferation.
CONCLUSIONS: Pancreatic cancer is characterized by a high expression of p53 and a low expression of bcl-2. In pancreatic cancers and pancreatic intraepithelial neoplasia, there is an inverse relationship between the expression of bcl-2 and p53. Malignant behavior of pancreatic cancer may be associated with the phenotype bcl-2-/p53+.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10732293     DOI: 10.1385/IJGC:26:3:163

Source DB:  PubMed          Journal:  Int J Pancreatol        ISSN: 0169-4197


  27 in total

1.  p53 protein expression as prognostic factor in human pancreatic cancer.

Authors:  Y Sato; Y Nio; M M Song; S Sumi; N Hirahara; Y Minari; K Tamura
Journal:  Anticancer Res       Date:  1997 Jul-Aug       Impact factor: 2.480

2.  bax, but not bcl-2, influences the prognosis of human pancreatic cancer.

Authors:  H Friess; Z Lu; H U Graber; A Zimmermann; G Adler; M Korc; R M Schmid; M W Büchler
Journal:  Gut       Date:  1998-09       Impact factor: 23.059

3.  The prognostic significance of p53 and bcl-2 expression in lung adenocarcinoma and its correlation with Ki-67 growth fraction.

Authors:  H Ishida; K Irie; T Itoh; T Furukawa; O Tokunaga
Journal:  Cancer       Date:  1997-09-15       Impact factor: 6.860

4.  Apoptosis and immunohistochemical bcl-2 expression in colorectal adenomas and carcinomas. Aspects of carcinogenesis and prognostic significance.

Authors:  G B Baretton; J Diebold; G Christoforis; M Vogt; C Müller; K Dopfer; K Schneiderbanger; M Schmidt; U Löhrs
Journal:  Cancer       Date:  1996-01-15       Impact factor: 6.860

5.  The classification of ductal carcinoma in situ and its association with biological markers.

Authors:  L G Bobrow; L C Happerfield; W M Gregory; R D Springall; R R Millis
Journal:  Semin Diagn Pathol       Date:  1994-08       Impact factor: 3.464

6.  Tumor suppressor p53 is a regulator of bcl-2 and bax gene expression in vitro and in vivo.

Authors:  T Miyashita; S Krajewski; M Krajewska; H G Wang; H K Lin; D A Liebermann; B Hoffman; J C Reed
Journal:  Oncogene       Date:  1994-06       Impact factor: 9.867

7.  Morphological lesions associated with human primary invasive nonendocrine pancreas cancer.

Authors:  A L Cubilla; P J Fitzgerald
Journal:  Cancer Res       Date:  1976-07       Impact factor: 12.701

8.  Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma.

Authors:  S Nakamura; K Akazawa; N Kinukawa; T Yao; M Tsuneyoshi
Journal:  Hum Pathol       Date:  1996-03       Impact factor: 3.466

9.  bcl-2 and p53 expression in resectable pancreatic adenocarcinomas: association with clinical outcome.

Authors:  F A Sinicrope; D B Evans; S D Leach; K R Cleary; C J Fenoglio; J J Lee; J L Abbruzzese
Journal:  Clin Cancer Res       Date:  1996-12       Impact factor: 12.531

10.  The bcl-2 candidate proto-oncogene product is a 24-kilodalton integral-membrane protein highly expressed in lymphoid cell lines and lymphomas carrying the t(14;18) translocation.

Authors:  Z Chen-Levy; J Nourse; M L Cleary
Journal:  Mol Cell Biol       Date:  1989-02       Impact factor: 4.272

View more
  4 in total

1.  Recombinant human adenovirus-p53 improves the outcome of mid-late stage pancreatic cancer via arterial infusion.

Authors:  Jinggang Mo; Meihua Lin; Bin He; Kai Tan; Chong Jin; Hao Jiang; Xuefeng Pan; Weidong Lin
Journal:  Oncol Lett       Date:  2017-09-25       Impact factor: 2.967

2.  TGF-beta and p53 staining in CT-guided and endoscopic ultrasound fine-needle aspirates of pancreatic adenocarcinoma.

Authors:  Dawn Sears; Richard A Erickson; Lubna Sayage-Rabie; Martha C Escobar
Journal:  Dig Dis Sci       Date:  2004-05       Impact factor: 3.199

3.  p53 protein expression and CA19.9 values in differential cytological diagnosis of pancreatic cancer complicated with chronic pancreatitis and chronic pancreatitis.

Authors:  De-Qing Mu; Guo-Feng Wang; Shu-You Peng
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

4.  Expression of Beclin 1 and Bcl-2 in pancreatic neoplasms and its effect on pancreatic ductal adenocarcinoma prognosis.

Authors:  Shanshan Song; Baosheng Wang; Shuailin Gu; Xiaocheng Li; Shaolong Sun
Journal:  Oncol Lett       Date:  2017-10-18       Impact factor: 2.967

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.